Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for Postoperative Depression in Breast Cancer
NCT04303325Phase 4Recruiting
- Sponsor
- China Medical University
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esketamine in major depressive disorder (MDD) (2 arms), sponsored by China Medical University. Primary endpoint: Montgomery-Asberg Depression Rating Scale. Started Oct 2021; status: recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04303325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303325.